COMPANY RESEARCHKintor Pharmaceutical Ltd
Kintor Pharmaceutical is a Chinese drug-development company working on targeted treatments for dermatological and other diseases. Its therapeutic research has included androgen-receptor-directed compounds, topical treatments for androgenetic alopecia, and experimental approaches aimed at oncology targets. Kintor is publicly listed in Hong Kong under stock code 9939. While the group also describes work involving dermatology-related cosmetic ingredients, that activity is distinct from its investigational therapeutic drug programs. The company maintains research and development operations in Suzhou and provides updates through its corporate website and stock-exchange disclosures.
Company at a glance
Corporate information
- Company entity
- Kintor Pharmaceutical Limited／开拓药业
- Headquarters / principal office
- 苏州, 江苏省Self-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2009
Sources (1)
- Company ProfileNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- Company ProfileNot stated
- Official corporate reference
- https://en.kintor.com.cn/
Sources (1)
- Company ProfileNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Kintor Pharmaceutical Limited 公司主页Not stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Kintor Pharmaceutical is a Chinese drug-development company working on targeted treatments for dermatological and other diseases. Its therapeutic research has included androgen-receptor-directed compounds, topical treatments for androgenetic alopecia, and experimental approaches aimed at oncology targets. Kintor is publicly listed in Hong Kong under stock code 9939. While the group also describes work involving dermatology-related cosmetic ingredients, that activity is distinct from its investigational therapeutic drug programs. The company maintains research and development operations in Suzhou and provides updates through its corporate website and stock-exchange disclosures.
HKEX: 09939
androgen receptor modulation · targeted small molecules · protein degradation
dermatology · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
GT20029 is a topical AR PROTAC. A 2024 announcement reports that the China Phase 2 male androgenetic alopecia study met its primary endpoint.
Business, technology & evidence
- A topical local skin-exposure strategy should be compared separately from systemic oral PROTACs.
- Kintor Pharmaceutical is a Chinese drug-development company working on targeted treatments for dermatological and other diseases. Its therapeutic research has included androgen-receptor-directed compounds, topical treatments for androgenetic alopecia, and experimental approaches aimed at oncology targets. Kintor is publicly listed in Hong Kong under stock code 9939. While the group also describes work involving dermatology-related cosmetic ingredients, that activity is distinct from its investigational therapeutic drug programs. The company maintains research and development operations in Suzhou and provides updates through its corporate website and stock-exchange disclosures.
- SecuritiesHKEX: 09939
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| GT20029 | AR · Androgenetic alopecia / acne | Phase 2 | Human results reported by the source; see facts and original materials for type and quality |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- KX-826 Phase 3 or commercialization plans must not be assigned to GT20029. Subsequent GT20029 Phase 2b / Phase 3 initiation requires a new registry confirmation.
- GT20029 China Phase II AGA endpoint ↗Kintor · 2024-04-21
- Development milestones ↗Kintor · Undated · 2026-10-31accessed
- Official issuer and R&D disclosure · Kintor Pharmaceutical Ltd ↗Kintor Pharmaceutical Ltd ·
- Official issuer and R&D disclosure · Kintor Pharmaceutical Ltd ↗Kintor Pharmaceutical Ltd ·
- Official issuer and R&D disclosure · Kintor Pharmaceutical Ltd ↗Kintor Pharmaceutical Ltd ·
- Company Profile ↗Kintor · Not stated
- Kintor Pharmaceutical Limited 公司主页 ↗Kintor／LinkedIn · Not stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.